- Home
- MGEE vs XENE Comparison
MGEE vs XENE Comparison
Compare MGEE & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | XENE |
|---|---|---|
| Founded | 1855 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MGEE | XENE |
|---|---|---|
| Price | $78.54 | $44.94 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $79.00 | $53.91 |
| AVG Volume (30 Days) | 133.4K | ★ 749.5K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 12.85 | N/A |
| EPS | ★ 3.69 | N/A |
| Revenue | ★ $708,516,000.00 | $7,500,000.00 |
| Revenue This Year | $10.69 | N/A |
| Revenue Next Year | $3.32 | N/A |
| P/E Ratio | $21.34 | ★ N/A |
| Revenue Growth | ★ 8.39 | N/A |
| 52 Week Low | $77.46 | $26.74 |
| 52 Week High | $96.25 | $46.60 |
Technical Indicators
Market Signals| Indicator | MGEE | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 57.85 |
| Support Level | $77.92 | $43.41 |
| Resistance Level | $79.24 | $46.25 |
| Average True Range (ATR) | 1.31 | 1.30 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 14.41 | 63.83 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.